Yi An, MD
Associate Professor of Therapeutic RadiologyCards
About
Research
Publications
2026
Association Between Perirectal Spacer Use and Short-Term Complications After Prostate Radiation Therapy in a National Claims-Based Analysis
Palencia P, Xi X, Zhao X, Ward B, Smani S, Sivanesan N, Diaz G, Miszczyk M, Fazekas T, Rajwa P, Cavallo J, Aneja S, An Y, Kim I, Leapman M. Association Between Perirectal Spacer Use and Short-Term Complications After Prostate Radiation Therapy in a National Claims-Based Analysis. Urology Practice 2026, 13: 405-412. PMID: 41810984, DOI: 10.1097/upj.0000000000000996.Peer-Reviewed Original ResearchEfficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis
Miszczyk M, Sohoni N, Smani S, Moll M, Alfarhan A, Roessler N, Miyajima K, Inoue S, Marvaso G, Mastroleo F, Zamboglou C, Soeterik T, Zilli T, Terlizzi M, Blanchard P, Rajwa P, Fazekas T, Ploussard G, An Y, Leapman M, Blanck O, Jereczek-Fossa B, Shariat S. Efficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis. Radiotherapy And Oncology 2026, 218: 111445. PMID: 41713502, DOI: 10.1016/j.radonc.2026.111445.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
Nguyen P, Kollmeier M, Rathkopf D, Hoffman K, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M. FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. European Urology 2026 PMID: 41672869, DOI: 10.1016/j.eururo.2025.12.001.Peer-Reviewed Original Research
2025
Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden
Palencia P, Smani S, Zhao X, Kandala K, Sivanesan N, Cavallo J, Roessler N, Aneja S, An Y, Miszczyk M, Leapman M. Association between prostate radiotherapy and survival among patients with metastatic prostate cancer by extent of disease burden. Radiotherapy And Oncology 2025, 213: 111158. PMID: 40987387, DOI: 10.1016/j.radonc.2025.111158.Peer-Reviewed Original Research
2024
Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024, 8: 1101-1110. PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchDevelopment of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.Peer-Reviewed Original ResearchSynthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells
Lee D, Huntoon K, Wang Y, Kang M, Lu Y, Jeong S, Link T, Gallup T, Qie Y, Li X, Dong S, Schrank B, Grippin A, Antony A, Ha J, Chang M, An Y, Wang L, Jiang D, Li J, Koong A, Tainer J, Jiang W, Kim B. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nature Biomedical Engineering 2024, 8: 593-610. PMID: 38641710, PMCID: PMC11162332, DOI: 10.1038/s41551-024-01194-7.Peer-Reviewed Original Research
2023
Retraction notice to “Two transition metal coordination polymers: Magnetic investigation and treatment activity on children chronic myocarditis by regulating the hs-cTnT expression” [J. Solid State Chem. 294 (2021) 121819]
Li S, Fan L, Dong X, An Y, Chen Z, Wang X, Yang B, Wang F. Retraction notice to “Two transition metal coordination polymers: Magnetic investigation and treatment activity on children chronic myocarditis by regulating the hs-cTnT expression” [J. Solid State Chem. 294 (2021) 121819]. Journal Of Solid State Chemistry 2023, 320: 123885. DOI: 10.1016/j.jssc.2023.123885.Peer-Reviewed Original Research
2022
Downregulation of Sirt6 by CD38 promotes cell senescence and aging
Zhou H, Liu S, Zhang N, Fang K, Zong J, An Y, Chang X. Downregulation of Sirt6 by CD38 promotes cell senescence and aging. Aging 2022, 14: 9730-9757. PMID: 36490326, PMCID: PMC9792202, DOI: 10.18632/aging.204425.Peer-Reviewed Original ResearchAssociation of circulating markers with cognitive decline after radiation therapy for brain metastasis.
Huntoon K, Anderson S, Ballman K, Twohy E, Dooley K, Jiang W, An Y, Li J, von Roemeling C, Qie Y, Ross O, Cerhan J, Whitton A, Greenspoon J, Parney I, Ashman J, Bahary J, Hadjipanayis C, Urbanic J, Farace E, Khuntia D, Laack N, Brown P, Roberge D, Kim B. Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. Neuro-Oncology 2022, 25: 1123-1131. PMID: 36472389, PMCID: PMC10237411, DOI: 10.1093/neuonc/noac262.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
IRB ID2000027702RoleSub InvestigatorPrimary Completion Date10/01/2025Recruiting Participants
Clinical Care
Overview
Yi An, MD, is a radiation oncologist in the Department of Therapeutic Radiology at Yale Medicine. He specializes in treating head and neck, gastrointestinal, prostate and lung cancers.
“I am so fortunate to have the privilege of taking care of cancer patients,”
Dr. An says. “Every day, I have the special opportunity to get to know and form lasting relationships with my patients.” Dr. An is trained in modern radiation treatment techniques, including intensity-modulated radiation therapy, stereotactic body radiation therapy and stereotactic radiosurgery. These cutting-edge radiation techniques, Dr. An says, can target and destroy cancer cells while also minimizing radiation doses to normal tissue and reduce the risk of side effects of treatment.
“Being with my patients at perhaps their most trying time in life,” he says, “drives me to do everything possible to cure their disease and alleviate their pain.”
At Yale School of Medicine, Dr. An is an assistant professor of therapeutic radiology.
Clinical Specialties
Prostate & Genitourinary Radiotherapy; Urologic Oncology; Neuro-Oncology
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale MedicineMetastatic Brain Tumors
Learn More on Yale MedicineRhabdomyosarcoma
Learn More on Yale Medicine
Yale Medicine News
News
News
- March 23, 2026
Yale Launches Innovative Clinical Trial for Metastatic Bladder Cancer
- November 19, 2024
2nd Annual Yale Urology Bulldog Debates Recap
- June 18, 2024
Combined Data Speak Volumes for Prostate Cancer Treatment
Get In Touch
Contacts
Email
Academic Office Number
Appointment Number
Clinical Inquiry Number
Office Fax Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.